In the 2027 Medicare Advantage (MA) and Part D rate announcement, CMS highlighted risk adjustment accuracy, payment integrity, and accountability for diagnoses that drive reimbursement.
CMS recently launched the Medicare GLP-1 Bridge, a short-term demonstration that provides eligible Part D beneficiaries with access to certain glucagon‐like peptide‐1 (GLP-1) drugs for $50 per month.
CMS released the fiscal year (FY) 2027 Inpatient Prospective Payment System (IPPS) final rule last week, outlining upcoming changes to Medicare payment rates and policies for inpatient services.
It’s essential to go beyond surface-level knowledge and gain a true understanding of how and why social determinants of health (SDOH) data is important to track, especially for pediatric patients.
